374 related articles for article (PubMed ID: 35081970)
21. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B.
Zeng Q; Chen S; You Z; Yang F; Carey TE; Saims D; Wang CY
J Biol Chem; 2002 Jul; 277(28):25203-8. PubMed ID: 11994287
[TBL] [Abstract][Full Text] [Related]
23. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.
Kumar D; Kandl C; Hamilton CD; Shnayder Y; Tsue TT; Kakarala K; Ledgerwood L; Sun XS; Huang HJ; Girod D; Thomas SM
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1133-9. PubMed ID: 26540318
[TBL] [Abstract][Full Text] [Related]
24. Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression.
Kumar D; New J; Vishwakarma V; Joshi R; Enders J; Lin F; Dasari S; Gutierrez WR; Leef G; Ponnurangam S; Chavan H; Ganaden L; Thornton MM; Dai H; Tawfik O; Straub J; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Van Houten B; Anant S; Krishnamurthy P; Thomas SM
Cancer Res; 2018 Jul; 78(14):3769-3782. PubMed ID: 29769197
[TBL] [Abstract][Full Text] [Related]
25. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
27. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma.
Lai JP; Chien J; Strome SE; Staub J; Montoya DP; Greene EL; Smith DI; Roberts LR; Shridhar V
Oncogene; 2004 Feb; 23(7):1439-47. PubMed ID: 14973553
[TBL] [Abstract][Full Text] [Related]
28. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
29. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.
Madoz-Gúrpide J; Zazo S; Chamizo C; Casado V; Caramés C; Gavín E; Cristóbal I; García-Foncillas J; Rojo F
J Transl Med; 2015 Aug; 13():282. PubMed ID: 26319934
[TBL] [Abstract][Full Text] [Related]
30. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
[TBL] [Abstract][Full Text] [Related]
31. Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma.
Susuki D; Kimura S; Naganuma S; Tsuchiyama K; Tanaka T; Kitamura N; Fujieda S; Itoh H
Cancer Sci; 2011 Dec; 102(12):2164-71. PubMed ID: 21899661
[TBL] [Abstract][Full Text] [Related]
32. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
33. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
34. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
35. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
36. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
[TBL] [Abstract][Full Text] [Related]
37. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
38. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
39. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
40. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]